A compound of the formula (1) or a pharmaceutically-acceptable salt wherein, for example, A is phenylene or heteroarylene; Y is selected from —C(O)R
2
, —C(O)OR
2
, —C(O)NR
2
R
3
, -(1-4C)alkyl [optionally substituted]-(2-4C)alkenyl, —SO
2
NR
2
R
3
, and —S(O)
c
R
2
(wherein c is 0, 1 or 2); compounds which possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.
式 (1) 的化合物或药学上可接受的盐 其中,例如,A 是亚苯基或杂芳基;Y 选自-C(O)R
2
、-C(O)OR
2
、-C(O)NR
2
R
3
-(1-4C)烷基[任选取代的]-(2-4C)烯基,-SO
2
NR
2
R
3
和 -S(O)
c
R
2
(其中 c 为 0、1 或 2);这些化合物具有
糖原磷酸化酶抑制活性,因此在治疗与
糖原磷酸化酶活性增加有关的疾病方面具有价值。本文介绍了化合物的生产工艺以及含有这些化合物的药物组合物。